RD102 / IASO BIO 
Welcome,         Profile    Billing    Logout  
  Diseases    Trials    Trials    News 
1 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
RD102 / IASO BIO
ChiCTR1900023922: An open-label, single-center and single-arm clinical study of infusion of anti-CD19 or CD22 CAR-T cells (CT101A-19 or CT102A-22) for patients with relapsed/refractory/high risk B cell malignancies.

Recruiting
N/A
50
 
Chimeric Antigen Receptor T-Cell Immunotherapy
Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology; Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Nanjing Iaso Biotherapeutics Co., Ltd.
B cell malignancies
 
 

Download Options